我要投票 健民龙牡在中草药行业中的票数:74
· 外 推 电 报 ·
2025-02-05 18:44:53 星期三

【健民龙牡是哪个国家的品牌?】

健民龙牡是什么牌子?「健民龙牡」是 健民药业集团股份有限公司 旗下著名品牌。该品牌发源于湖北,由创始人刘勤强在1993期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

龙牡壮骨颗粒是武汉健民集团旗下一个有着近20年辉煌历史、创造了中国医药界长盛不衰奇迹的知

名品牌,整整抚育了中国两代儿童的健康成长。
龙牡壮骨颗粒的的主要药材(如茯苓、麦冬等)都直接选用武汉健民集团专门建设的GAP药材种植

基地的原料,药材天然地道。生产过程中的每个环节、每道工序都有严格的质控标准,做到了“不合

格的原料不进厂,不合格的半成品不转到下道工序,不合格的产品不出厂”。

龙牡壮骨颗粒问世18年,畅销了18年,累计60亿袋的产量。“龙牡”的面世和畅销,创造了令人惊叹

的市场业绩和品牌价值,也使得武汉健民——一个有着悠久历史、而却依然年轻的企业焕发出勃勃的

生机,从此享誉长城内外,大江南北。

“龙牡”,曾经独领儿童补钙产品市场的风骚。而如今,它却受到了来自其它同类竞品的强力竞

争和挑战,面临着市场份额被不断蚕食和瓜分的严峻局面。

抚育了中国整整二代人的茁壮成长。

1985年在武汉市儿童医院出生,填补了我国以中药为主体,防治小儿佝偻病的空白;

1990年被收载入湖北省药品标准;

1992年被列为国家唯一的补钙一级中药保护品种;

1993年被中国儿童保护中心推荐为最佳小儿补钙、促进钙质吸收药品;

1994年被全国佝偻病防治协作组列为首推中成药;

1995年被收载入卫生部药品标准;

1999年被列为国家基本药物;

2000年被中国药典2000版收载;

2002年被列为国家处方药与非处方药(OTC)双跨品种;

同年,被《中医儿科学》(新世纪全国高等中医院校规划教材)收载。

武汉健民为中国医药工业50强企业,集团股份有限公司是国家重点高新技术企业、全国中成药小儿用药生产基地、全国重点中药企业。集团的前身是中国最古老的四大中药名店之一的叶开泰药店,距今已有近四个世纪的历史,现拥有十余个子公司,集生产、科研、经贸于一体,年生产能力近十亿元。

改革开放以来,集团公司以振兴民族医药为己任,积极推进企业改革,不断探索新的管理体制和运行机制,大力提高企业创新能力,促进了公司的全面发展,企业获得了比以往任何时候都好的社会效益和经济效益,创造了国有企业稳健经营的奇迹,综合实力跻身于全国企业500强和行业50强。近几年,集团大力实施科技兴业战略,确立了坚持以中药研发、生产和销售为主业,重点开发市场急需的小儿用药,老年用药和重大疑难病症用药,构建以中药现代化、产业化为基础,以高新技术药品为支撑的科技先导型医药集团。

目前,健民集团已成功地研制和开发出以龙牡壮骨颗粒、健民咽喉片、健脾生血颗粒、便通胶囊、慢肝宁胶囊为代表的系列产品,形成了集团蔚为壮观的"名牌林",产品行销全国,远销东南亚及欧美国家和地区。集团在近些年中相继荣获"全国质量效益型先进企业"、"全国中药行业优秀企业"、"全国五一劳动奖状"等称号,被誉为"搞好搞活国有企业的一面旗帜","健民"商标亦荣获"中国驰名商标"称号。一个以中药产业为基础,以高新科技为特征的健民集团必将在新的世纪里创更辉煌的业绩,谱写出振兴国药的优美乐章。

英文翻译:Longmu Zhuanggu Granule is a well-known brand under Wuhan Jianmin group, which has a glorious history of nearly 20 years and has created a long-lasting miracle in the field of Chinese medicine. It has nurtured the healthy growth of two generations of children in China. The main medicinal materials of Longmu Zhuanggu granules (such as Poria cocos, Ophiopogon japonicus, etc.) are directly selected from the gap medicinal materials planting base specially built by Wuhan Jianmin group, which are natural and authentic. There are strict quality control standards for each link and process in the production process, so that "unqualified raw materials are not allowed to enter the factory, unqualified semi-finished products are not transferred to the next process, and unqualified products are not allowed to leave the factory". Longmu Zhuanggu granules have been produced for 18 years and have been popular for 18 years, with a total output of 6 billion bags. The appearance and best-selling of "Longmu" has created amazing market performance and brand value, and also made Wuhan Jianmin, an enterprise with a long history but still young, full of vitality. Since then, it has been famous inside and outside the Great Wall, North and south of the river. "Longmu" once led the market of children's calcium supplement products. But now, it is faced with strong competition and challenge from other competitors, and the market share is constantly eroded and divided. He nurtured two generations of Chinese people. Born in Wuhan children's Hospital in 1985, it has filled in the blank of prevention and treatment of rickets in China with traditional Chinese medicine as the main body; in 1990, it was included in the drug standard of Hubei Province; in 1992, it was listed as the only one level of protection of traditional Chinese medicine for calcium supplement; in 1993, it was recommended as the best drug for children's calcium supplement and calcium absorption by China children's protection center; in 1994, it was recommended by the National Coordination Group for prevention and treatment of rickets It was listed as the first Chinese patent medicine; in 1995, it was listed in the drug standard of the Ministry of health; in 1999, it was listed as the national basic drug; in 2000, it was listed in the 2000 edition of the Chinese Pharmacopoeia; in 2002, it was listed as the national prescription medicine and over-the-counter medicine (OTC) double cross varieties; in the same year, it was listed in the pediatrics of traditional Chinese medicine (the textbook for the planning of the national higher education of traditional Chinese medicine in the new era). Wuhan Jianmin is one of the top 50 enterprises in China's pharmaceutical industry. The Group Co., Ltd. is a national key high-tech enterprise, a national production base of Chinese patent medicine for children and a national key Chinese medicine enterprise. The group's predecessor is Ye Kaitai drugstore, one of the four oldest famous traditional Chinese medicine stores in China. It has a history of nearly four centuries. Now it has more than ten subsidiaries, integrating production, scientific research and economic and trade, with an annual production capacity of nearly one billion yuan. Since the reform and opening up, the group company has taken the revitalization of national medicine as its own duty, actively promoted the enterprise reform, constantly explored new management system and operation mechanism, vigorously improved the innovation ability of the enterprise, promoted the overall development of the company, obtained better social and economic benefits than ever before, created a miracle of steady operation of state-owned enterprises, and its comprehensive strength ranks among Top 500 enterprises and top 50 industries in China. In recent years, the group has vigorously implemented the strategy of developing industry through science and technology, established a science and technology leading pharmaceutical group based on the modernization and industrialization of traditional Chinese medicine, supported by high-tech drugs, which adheres to the R & D, production and sales of traditional Chinese medicine as the main business, focuses on the development of children's drugs, elderly drugs and drugs for major and difficult diseases urgently needed in the market. At present, Jianmin group has successfully developed and developed a series of products represented by Longmu Zhuanggu granules, Jianmin Yanhou tablets, Jianpi Shengxue granules, Bentong capsules and manganning capsules, forming a spectacular "famous brand forest" of the group, which is sold all over the country and exported to Southeast Asia, European and American countries and regions. In recent years, the group has been awarded the titles of "national advanced quality and benefit enterprise", "national excellent enterprise in traditional Chinese medicine industry", "National May 1st Labor Award", etc., and is honored as "a banner for invigorating state-owned enterprises", and the "invigorating the people" trademark has also won the title of "China famous trademark". A Jianmin group based on traditional Chinese medicine industry and characterized by high and new technology is bound to make more brilliant achievements in the new century and compose a beautiful movement to revitalize traditional Chinese medicine.

本文链接: https://www.waitui.com/brand/f7f9487ec.html 联系电话:027-84523252

千城特选小程序码

7×24h 快讯

慈星股份:终止筹划购买武汉敏声控股权并配套募资事项,股票明起复牌

36氪获悉,慈星股份公告,公司因筹划发行股份及支付现金购买武汉敏声新技术有限公司控股权并募集配套资金事项,公司股票自2025年1月15日开市时起开始停牌。经交易相关方商讨研究决定终止筹划本次交易事项,公司股票将于2025年2月6日(星期四)开市起复牌。 截至公告日,交易各方未就本次交易具体方案、交易条件达成最终实质性协议。

45分钟前

汇丰控股:昨日耗资约1.76亿港元回购219.76万股公司股份

36氪获悉,汇丰控股公告,公司于2月4日耗资约1.76亿港元回购219.76万股公司股份,每股回购价格79.6港元-80.45港元。

45分钟前

印尼网约车巨头GoTo否认与Grab合并传闻

印尼网约车巨头GoTo当地时间2月4日提交文件,否认同竞争对手Grab的合并传闻。该公司称,“除实施股票回购外,未来12个月内没有任何重大行动计划”。此前有市场消息称,Grab与GoTo最近几周加快协商,认为今年是达成交易的有利时机。两家公司上市后均逐渐朝向取得盈利迈进,但竞争激烈导致价格无法调涨,同时挤压利润空间。据报道,过去几年双方一直在断断续续地协商,合并障碍包括双方之间的分歧,以及两家公司在印尼、新加坡等市场主导地位可能带来的反垄断问题。(界面)

45分钟前

众鑫股份:泰国工厂一车间正式投产,预计2025年完成产量3万吨以上

36氪获悉,众鑫股份公告,公司泰国工厂一车间已顺利安装完毕,并于2025年1月8号开始调试设备并试机生产,2月1日顺利完成试机并正式投产。同时,二车间开始安装设备。公司预计2025年完成产量3万吨以上,2026年完成产量5万吨。此外,公司将根据国际市场的变化情况,决策是否对泰国工厂实施扩产计划。本次试机成功为公司拓展海外业务打下了基础,也验证了新装备的先进性,为今后的装备研发与升级提供了宝贵经验。

45分钟前

杭州银行:2024年净利润169.83亿元,同比增长18.08%

36氪获悉, 杭州银行发布业绩快报,2024年度实现营业收入383.81亿元,同比增长9.61%;归属于上市公司股东的净利润169.83亿元,同比增长18.08%。截至2024年末,公司总资产21125.91亿元,较上年末增长14.73%;贷款总额9374.99亿元,较上年末增长16.16%;存款总额12725.51亿元,较上年末增长21.74%。

45分钟前

本页详细列出关于前列康的品牌信息,含品牌所属公司介绍,前列康所处行业的品牌地位及优势。
咨询